APi Group Corporation (NYSE: APG) shares are 19.01% up in the year-to-date (YTD) period and have moved 1.71% or $0.37 higher in the latest trading session. However, stock’s trailing 12-month performance remains nearly +31.69% lower. Comparatively, the stock is up 21.01% over the trailing 3-month period. If we look at the shorter duration, its weekly performance is 15.69% and 10.43% over the month.
On June 24, 2020, Robert W. Baird recommended the APG stock is an Outperform, while earlier, Barclays had Initiated the stock as an Overweight on September 22, 2020. 0 of the 6 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 4 recommend buying, with 1 rating it as an Overweight.
The stock currently trades at $21.97 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $23.20. The forecasts give the APi Group Corporation stock a price target range of $25.00 on the higher side while at least one analyst thinks the stock could plunge to a low of $22.00. The two limits represent an upside potential of 12.12% or 0.14%.
For the current year, earnings should grow to an average of $1.17, up 3.20% from $1.22 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between $0.29 and $0.34. Wall Street estimates earnings per share to be at an average of $1.3 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 26 over the last 12 months, while SEC filings reveal that there have been 11 insider sales over the same period. Insiders have purchases 11,945,934 shares while those sold by company executives and officers stand at 3,126,828. The last 3 months have seen insiders trade a total of 55,508 and 16,697 in purchases and sales respectively.
Becker Russell A., a PRESIDENT, AND CEO at the company bought 2,100 shares worth $30009.0 at $14.29 per share on Jun 19. The CHIEF LEARNING OFFICER had earlier bought another 70,000 APG shares valued at $1.03 million on Aug 14. The shares were bought at $14.74 per share.
Sustainable Green Team, Ltd. (SGTM) plunged -1.26% to $2.35. Its market capitalization arrived at $210,309,502. The stock has a 52-week high price of $7.00 and its 52-week low was recorded at $1.00, while during last trade its minimum price was $2.35 and it gained the highest price of $2.35.
During the third quarter of 2020, the Company achieved these notable achievements.
- Changes to the Company’s name and its stock symbol was completed on July 21.
- Reducing the number of shares authorized from 3,249,000,000 to 250,000,000, a 93% reduction, as of July 21.
- Receiving IPEMA certification to turn tree and storm waste into a $4 billion market, surfacing material for public playgrounds, on July 23.
- Construction of a Waste Management landfill facility completed on July 28, increasing mulch manufacturing capabilities.
- The Company announced Aug. 5 that it had added new grapple hauling trucks to its fleet, expanding vertically integrated operations.
- The Company has received permit approval for mulch manufacture at their largest state-of-the-art facility, announced Aug. 13.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), on the other hand, is trading around $12.99 with a market cap of $1.67B and analyst research firms have a negative stance on its shares. Analysts predict that the stock will reach $11.50 and spell out a less modest performance – a -12.96% return. Some analysts are even forecasting -$1.01 per share in earnings this year on a short-term (1 year) basis.
Let us briefly look at the Aurinia Pharmaceuticals Inc. (AUPH) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
AUPH’s operating expenses over the recent quarter were at -$8.79 million. This represented 117.57% of the company’s total revenues which amounted $50.03 million. With this in place, we can see that the company’s diluted EPS declined -$0.18 on the year-over-year period, shrinking to -$0.43 as given in the last earnings report.
In terms of the balance sheet & cash flow as of Dec 2017, the total assets figure advanced to $463.66 million from $461.75 million over the previous quarter. Short term investments amounted to $125.98 million while total current assets were at $419.43 million. The cash flow from operating activities totaled -$69.86 million, significantly lower than the -$63.59 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$75.44 million.
Insiders have transacted a total of 8 times at Aurinia Pharmaceuticals Inc. over the last 6 months, with insider purchases undertaken 7 times and accounting for 137,500 shares. Insider sales totaled 40,000 shares over the same period, with these deals completed in 1 transaction. Looking at these numbers, we realize that net purchases over that period are 6.0 shares. Insiders now hold a total of 9.23M shares after the latest sales, with 1.10% net shares purchased.
Insiders own 7.24% of the company shares, while shares held by institutions stand at 50.34% with a share float percentage of 116.02M. Investors are also buoyed by the number of investors in a company, with Aurinia Pharmaceuticals Inc. having a total of 208 institutions that hold shares in the company. The top two institutional holders are Healthcor Management LP with over 6.94 million shares worth more than $95.94 million. As of Dec 30, 2020, Healthcor Management LP held 5.44% of shares outstanding.
The other major institutional holder is FMR, LLC, with the investment firm holding over 5.76 million shares as of Dec 30, 2020. The firm’s total holdings are worth over $79.7 million and represent 4.52% of shares outstanding.